Ex Parte Her et al - Page 5




                    Appeal No. 2003-1092                                                                                                                                  
                    Application No. 09/692,730                                                                                                                            


                    overlaps the lysine concentration taught and claimed by the                                                                                           
                    Appellants.  Stated otherwise, as it presently exists, the                                                                                            
                    application file record reflects that the Examiner believes                                                                                           
                    at least some of the appealed claims are unpatentable over the                                                                                        
                    disclosure of Grumbine.  We will not here comment upon whether or                                                                                     
                    not such a belief is well founded since the appeal before us does                                                                                     
                    not present such an issue.                                                                                                                            
                              Nevertheless, the file record must be clarified in terms of                                                                                 
                    claim patentability versus unpatentability in relation to the                                                                                         
                    Examiner’s aforequoted statement.  This is because, in the absence                                                                                    
                    of clarification, the Examiner’s statement could be interpreted as                                                                                    
                    militating against the validity of any patent claims which might                                                                                      
                    issue from this application.  As a consequence, upon return of the                                                                                    
                    subject application to the jurisdiction of the Examining Corps, the                                                                                   
                    Examiner must address and resolve on the written record whether and                                                                                   
                    why he believes the slurry defined by some or all of the appealed                                                                                     
                    claims to be patentably distinguishable or indistinguishable from                                                                                     
                    the slurry disclosed by Grumbine.                                                                                                                     
                              For example, the Examiner may believe that an artisan in                                                                                    
                    formulating a slurry in accordance with Grumbine’s disclosure would                                                                                   
                    have found it obvious to select lysine specifically as a tungsten                                                                                     
                    etch/corrosion inhibiting agent and would have found it obvious to                                                                                    

                                                                                    55                                                                                    





Page:  Previous  1  2  3  4  5  6  7  8  Next 

Last modified: November 3, 2007